Shionogi to acquire ALS medications from Tanabe

Japanese pharma major Shionogi (TYO: 4507) today revealed that its board of directors has resolved to acquire a newly established company that Tanabe Pharma (now part of Bain Capital and previously known at Mitsubishi Tanabe) plans to form. This new entity will hold the rights to Radicava ORS (edaravone) and IV Radicava, and Shionogi intends to purchase 100% of its shares.

RadicavaORS is approved by the US Food and Drug Administration (FDA) and other regulatory agencies around the world for the treatment of amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease for which there is no cure and few treatment options. RadicavaORS, along with a previously available intravenous formulation, have been used to treat more than 20,000 people with ALS in the USA to date.

The global amyotrophic lateral sclerosis treatment market size was estimated at $667.3 million in 2023 and is projected to reach $987.6 million by 2030, growing at a CAGR of 5.8% from 2024 to 2030.